Summary
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
History
CareDx was founded in 1998 and offers the industry’s most comprehensive suite of diagnostic and monitoring solutions to improve transplant patient outcomes and quality of life. In addition to the AlloMap® molecular expression testing, and the Olerup brand of HLA typing products, CareDx also offers products and services for AlloSure®, a sensitive and specific non-invasive monitoring test for heart transplant rejection, and Cardea SOLO™, a single-sample molecular testing solution for measuring donor-derived cell-free DNA in transplant patients.
Mission
CareDx’s mission is to enable improved care for transplant recipients and other patients through the discovery, development and commercialization of innovative diagnostics.
Vision
CareDx is striving to be a world leader in precision medicine solutions for transplant patients.
Key Team
Mr. Marcel Konrad (Sr. VP of Fin. & Accounting)
Mr. Alexander L. Johnson (Pres of Patient and Testing Services)
Mr. Abhishek Jain (CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer)
Ms. Marica Grskovic Ph.D. (Chief Operating Officer)
Mr. Abraham Ronai Esq. (Gen. Counsel, Chief Admin. & Legal Officer and Sec.)
Mr. Ian Cooney (VP of Investor Relations)
Dr. Mickey Y. Kim M.D. (Sr. VP of Corp. Devel. & Head of Global Product)
Recognition and Awards
CareDx is proud to have received numerous awards and recognitions for our diagnostics and services, including the Frost & Sullivan Industry Excellence Award, Goldman Sachs Entrepreneur Award, the Silicon Valley Business Journal’s Best Places to Work Award, the Red Herring Global Top 100 Award, and the James Dyson Award. We are committed to furthering clinical research and development of new diagnostic solutions.
References
United States 